ArticleJournal of nanobiotechnology2026
Construction and evaluation of an engineered autonomously lysing Salmonella system coupled with self-assembled nanoparticles as a vaccine platform for antigen delivery.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Live attenuated Salmonella vectors hold great promise for antigen delivery due to their ability to elicit broad mucosal and systemic immunity, but their clinical translation is hindered by safety concerns (e.g., virulence reversion, persistent colonization) and suboptimal antigen release kinetics. Here, we devised and constructed a novel, programmed lysis system in Salmonella based on regulated delayed gene expression and integrated it with self-assembled nanoparticles to create a versatile vaccine platform. This programmed lysis system involved a tse1 gene from Pseudomonas aeruginosa (P. aeruginosa) encoding a peptidoglycan-cleaving lytic effector and a controllable promoter P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.